Regencell Bioscience (NASDAQ:RGC) Stock Price Up 11.1% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares shot up 11.1% during mid-day trading on Thursday . The company traded as high as $30.96 and last traded at $30.6610. 189,889 shares were traded during trading, a decline of 43% from the average session volume of 332,522 shares. The stock had previously closed at $27.59.

Key Headlines Impacting Regencell Bioscience

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: Pomerantz LLP announced a formal class action filed in the U.S. District Court for the District of Maryland against Regencell and certain officers covering the Oct. 28, 2024–Oct. 31, 2025 period, seeking damages under Sections 10(b) and 20(a). Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGC
• Negative Sentiment: Rosen Law Firm and related Rosen notices remind investors of a lead‑plaintiff deadline in mid‑June and solicit potential clients for the same securities‑fraud matter. Multiple Rosen releases increase publicity around the litigation. ROSEN Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel … – RGC
• Negative Sentiment: Levi & Korsinsky highlights allegations that Regencell may have misrepresented business fundamentals (citing a ~$1M R&D budget vs. a multibillion valuation) and reminds investors of the June lead‑plaintiff deadline—an allegation that, if pursued, could be materially damaging. Levi & Korsinsky Reminds Regencell Bioscience Holdings Investors … – RGC
• Negative Sentiment: Glancy Prongay Wolke & Rotter, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Robbins LLP and others have issued alerts or solicitations about the same class action and lead‑plaintiff timeline, amplifying investor awareness and potential participation in the suit. Examples: Glancy/BusinessWire, Bragar/GlobeNewswire, Bronstein/GlobeNewswire, Faruqi/PR Newswire, Robbins/PR Newswire. Glancy Prongay Wolke & Rotter LLP Encourages Regencell Shareholders To Inquire …
• Negative Sentiment: Kaplan Fox and other firms also posted investor alerts urging contact before the lead‑plaintiff deadline, adding to the volume of solicitations and press coverage around the litigation. RGC CLASS ACTION DEADLINE: Kaplan Fox Encourages Investors …

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The stock has a fifty day simple moving average of $27.07 and a two-hundred day simple moving average of $23.76.

Hedge Funds Weigh In On Regencell Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of RGC. Seven Fleet Capital Management LP bought a new position in Regencell Bioscience during the fourth quarter worth $92,000. Hudson Bay Capital Management LP bought a new position in Regencell Bioscience during the fourth quarter worth $275,000. XTX Topco Ltd bought a new position in Regencell Bioscience during the third quarter worth $598,000. Vident Advisory LLC lifted its stake in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after purchasing an additional 11,866 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the second quarter worth $768,000. Hedge funds and other institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.